Octagon Capital Advisors LP Cardiff Oncology, Inc. Transaction History

Octagon Capital Advisors LP

  • $414 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022
SELL
$2.11 - $7.25 $2.07 Million - $7.12 Million
-982,753 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$6.65 - $10.04 $2.21 Million - $3.34 Million
332,753 Added 51.19%
982,753 $6.54 Million
Q4 2020

Feb 16, 2021
BUY
$12.02 - $24.71 $7.81 Million - $16.1 Million
650,000 New
650,000 $11.7 Million

Others Institutions Holding CRDF

# of Institutions
90
Shares Held
12.3M
Call Options Held
813K
Put Options Held
91.1K
View Full List

About Cardiff Oncology, Inc.

CRDF Quotes by TradingView
  • Ticker CRDF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,334,900
  • Market Cap $110M
  • Description
  • Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...
More about CRDF
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email